Maria K Magnusson1, Rahil Dahlén1, Hans Strid2, Stefan Isaksson1, Magnus Simrén2, Anders Lasson3, Antal Bajor2, Kjell-Arne Ung4, Lena Ohman1. 1. Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, Sweden ; Department of Microbiology and Immunology, Sahlgrenska Academy, University of Gothenburg, Sweden. 2. Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, Sweden. 3. Department of Internal Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, Sweden ; Södra Älvsborg Hospital, Borås, Sweden. 4. Kärnsjukhuset, Skövde, Sweden.
Abstract
BACKGROUND: Although infliximab treatment is an option for patients with ulcerative colitis (UC), not all patients do respond to therapy, and cellular mechanisms leading to therapy response are incompletely known. OBJECTIVE: The objective of this article is to determine early effects of infliximab therapy on T cells in the blood of UC patients and if effects differed in therapy responders and nonresponders. METHODS: Blood samples were obtained before and two weeks post-treatment start from 34 anti-tumor necrosis factor (TNF) therapy-naïve UC patients undergoing infliximab therapy. Response to therapy was evaluated prior to the fourth treatment dose. Expression of T cell surface markers and levels of soluble receptors and cytokines in serum were determined. RESULTS: At baseline, there were no differences in cellular, biochemical or clinical parameters between therapy responders and nonresponders. Infliximab therapy reduced frequencies of CD25(+) T cells and increased frequencies of annexin V(+) T cells in patients responding to infliximab, but not in nonresponding patients, two weeks after therapy start. Only therapy responders had decreased serum levels of sCD25 and sTNFRII two weeks after treatment start. In contrast, clinical parameters did not reflect therapy outcome already two weeks after therapy start. CONCLUSION: Soluble and membrane-bound T cell receptors may be early indicators of infliximab therapy response in UC, which can be of clinical importance for the decision when to continue or to stop the treatment.
BACKGROUND: Although infliximab treatment is an option for patients with ulcerative colitis (UC), not all patients do respond to therapy, and cellular mechanisms leading to therapy response are incompletely known. OBJECTIVE: The objective of this article is to determine early effects of infliximab therapy on T cells in the blood of UC patients and if effects differed in therapy responders and nonresponders. METHODS: Blood samples were obtained before and two weeks post-treatment start from 34 anti-tumor necrosis factor (TNF) therapy-naïve UC patients undergoing infliximab therapy. Response to therapy was evaluated prior to the fourth treatment dose. Expression of T cell surface markers and levels of soluble receptors and cytokines in serum were determined. RESULTS: At baseline, there were no differences in cellular, biochemical or clinical parameters between therapy responders and nonresponders. Infliximab therapy reduced frequencies of CD25(+) T cells and increased frequencies of annexin V(+) T cells in patients responding to infliximab, but not in nonresponding patients, two weeks after therapy start. Only therapy responders had decreased serum levels of sCD25 and sTNFRII two weeks after treatment start. In contrast, clinical parameters did not reflect therapy outcome already two weeks after therapy start. CONCLUSION: Soluble and membrane-bound T cell receptors may be early indicators of infliximab therapy response in UC, which can be of clinical importance for the decision when to continue or to stop the treatment.
Authors: Claudia Veltkamp; Matthias Anstaett; Kristin Wahl; Sarah Möller; Saskia Gangl; Oliver Bachmann; Matthias Hardtke-Wolenski; Florian Länger; Wolfgang Stremmel; Michael P Manns; Klaus Schulze-Osthoff; Heike Bantel Journal: Gut Date: 2011-04-01 Impact factor: 23.059
Authors: Nathalie Holmén; Anna Lundgren; Samuel Lundin; Ann-Marie Bergin; Anna Rudin; Henrik Sjövall; Lena Ohman Journal: Inflamm Bowel Dis Date: 2006-06 Impact factor: 5.325
Authors: Zhe Li; Ingrid Arijs; Gert De Hertogh; Séverine Vermeire; Maja Noman; Dominique Bullens; Lieve Coorevits; Xavier Sagaert; Frans Schuit; Paul Rutgeerts; Jan L Ceuppens; Gert Van Assche Journal: Inflamm Bowel Dis Date: 2010-08 Impact factor: 5.325
Authors: R Dahlén; H Strid; A Lundgren; S Isaksson; S Raghavan; M K Magnusson; M Simrén; H Sjövall; L Öhman Journal: Scand J Immunol Date: 2013-09 Impact factor: 3.487